Related Experiment Video
Updated: Feb 5, 2026

Assessing Specificity of Anticancer Drugs In Vitro
Published on: March 23, 2016
A dialogue on innovation in anticancer drug discovery
1Aurigene Oncology Limited 39-40, KIADB Industrial Area, Electronic City Phase II, Hosur Road Bangalore - 560100 India susanta_s@aurigene.com.
None:
Medicinal chemistry has driven the evolution of oncology drug discovery, transitioning from early cytotoxic agents to modern precision-guided therapies. This opinion article traces the historical trajectory of medicinal chemistry practices, beginning with the era of conventional chemotherapy and moving through the development of targeted therapies utilizing various precision oncology strategies. It then explores the recent wave of innovations-such as proximity inducers and drug conjugates-that have significantly redefined the druggable proteome. While these emerging modalities promise transformative benefits for patients, they also introduce unique challenges related to delivery, selectivity, and acquired resistance. We conclude with a perspective on the future of oncology that the integration of these novel strategies with computational design, advanced proteomics, and biomarker-driven approaches will be essential to accelerate the development of next-generation personalized cancer therapies.
More Related Videos
14:14The Innovation Arena: A Method for Comparing Innovative Problem-Solving Across Groups
Published on: May 13, 2022
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
Related Concept Videos
Drug Discovery: Overview
Pharmacokinetics: Drug–Drug Interactions
Bioequivalence of Drugs: Drugs with Multiple Indications
FDA Approved Drugs: Changes to Approved Drugs
Factors Influencing Drug Absorption: Drug Dissolution
Factors Affecting Protein-Drug Binding: Drug-Related Factors
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...